Immunotherapy in Advanced Hodgkin Lymphoma
Patients who received Opdivo and chemotherapy had better outcomes and fewer side effects than those who had the standard-of-care therapy.
Progress Against Cancer
Patients who received Opdivo and chemotherapy had better outcomes and fewer side effects than those who had the standard-of-care therapy.
An experimental antibody helped people recover body mass lost due to cancer and treatment.
Shorter, more intense radiation regimens may be as effective as traditional treatments, with greater convenience for patients.
People with metastatic hormone receptor-positive breast cancer are living longer, thanks to new targeted therapies and endocrine therapies that can be prescribed when treatment resistance develops.
Blood tests can guide treatment choices, delivering results in less time than traditional biopsies.
The FDA has approved the Immunotherapy durvalumab in combination with chemotherapy for certain patients with resectable bladder cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with chemotherapy before...
New prostate cancer surgery approach can prevent sexual side effects, and some people with esophageal cancer may be able to avoid surgery.
The FDA has approved the radiotherapy lutetium Lu 177 vipivotide tetraxetan for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for...
This month, the editors of AACR's journals tout studies showcasing the immunostimulatory impact of senescent cancer cells, a novel bispecific immunotherapy, and more.
A promising new personalized vaccine headlines several recent breakthroughs that highlight progress in kidney cancer research.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More